Heart Matters

Despite advances in lipid-lowering therapies, disparities in hyperlipidemia diagnosis and treatment persist. Dr. Keith Ferdinand examines how social drivers of health impact access, adherence, and outcomes and explains how clinicians can help address gaps in care for underserved populations. Dr. Ferdinand is a Professor of Medicine as well as the Gerald S. Berenson Chair in Preventative Cardiology...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Wilson Tang, MD Many different artificial sweeteners are being consumed by patients; however, this discussion will focus on research around one that has been used in the food industry for a long time, called erythritol. Interestingly, it was found that patients with cardiac problems had the highest levels of erythritol levels in their bl...

Host: Javed Butler, MD Guest: Michael J. LaMonte, PhD, MPH The American Heart Association recommends physical activity to help lower the risk of heart failure, but how much exercise is needed, especially for older women, to lower that risk? According to a recent study, even just low-intensity exercise for 30 minutes is associated with a 25 percent lower risk of overall heart failure. Dive further...

Host: Javed Butler, MD Guest: Jeffrey Wilson, MD There’s a decent amount of evidence showing allergic immune responses could have connections with heart disease. But with the knowledge gaps that exist, a need for bigger cohorts is necessary to get more information and data. So to explore the link between allergic reactions from food and heart disease, Dr. Javed Butler is joined by Dr. Jeffrey Wils...

Host: Javed Butler, MD Guest: Chiadi Ndumele, M.D., Ph. D., M.H.S. For the first time, the American Heart Association (AHA) has identified cardiovascular-kidney-metabolic (CKM) syndrome, which reflects a strong overlap between heart disease, kidney disease, and obesity. The major clinical consequence of CKM syndrome is multi-organ dysfunction with a particularly high incidence and burden of cardio...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Dave L. Dixon, PharmD, FACC,  FCCP, FNLA, BCPS, BCACP, CDE, CLS What would the cost-effectiveness look like if the uptake of a pharmacist-prescribing model for hypertension were to be put into practice? A new study shows that a pharmacist-prescribing method could have significant economic impact on the U.S. healthcare system. Dive in wit...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Javed Butler, MD There’s no approved therapies specifically targeting obesity and HFpEF, but based on the STEP-HFpEF study that was presented at the 2023 ESC Congress, the treatment option semaglutide improves heart failure-related symptoms, physical function, and weight loss among patients with HFpEF and obesity. Here to walk through th...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Steve Grinspoon, MD The risk of cardiovascular disease is twice as great among patients living with HIV, and this could partly be due to traditional risk factors, along with nontraditional risk factors. Here to discuss the results from the REPRIEVE study with Dr. Mary Katherine Cheeley is Dr. Steve Grinspoon, Co-Principal Investigator an...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA The National Lipid Association (NLA) recently published updated recommendations for lifestyle therapies to manage three common dyslipidemias in adults. To discuss this, Dr. Mary Katherine Cheeley is joined by Dr. Carol Kirkpatrick, Clinical Lipid Specialist and Clinical Scientist at Midwest Bio...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Steve Grinspoon, MD Many studies over the last few years have shown that the risks of cardiovascular disease have increased between 50 to 100 percent among patients with HIV. So what steps need to be taken to help reduce this risk for our patients? Here to discuss what we need to know is Dr. Mary Katherine Cheeley and Dr. Steven Grinspoo...

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Maya S. Safarova, MD, PhD, FNLA Learn which patients with low-density lipoprotein (LDL) would benefit from this group of medication. In this episode, Dr. Alan Brown is joined by Dr. Maya Safarova, Chief Fellow in the Department of Cardiovascular Medicine at the University of Kansas Medical Center, to discuss the benefits of non-statin LDL lowering t...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Alan S. Brown, MD, FACC, FAHA, FNLA Both clinical trials for lowering Lp(a) had patients with established atherosclerotic cardiovascular disease (ASCVD). Join in for a further discussion on important updates presented at the 2023 National Lipid Association Meeting with Dr. Mary Katherine Cheeley and fellow ReachMD host, Dr. Alan Brown, P...

Host: Javed Butler, MD Guest: John W. MacArthur With many barriers standing in the way of people in the United States who need a heart transplant, fewer than 10 percent of patients actually receive this life-saving surgery according to Stanford Medicine. Therefore, surgeons are working on different techniques to increase the pool of healthy donated hearts. To speak more about this, Dr. Javed Butle...

Host: Javed Butler, MD Guest: Pedro A Villablanca Spinetto, MD A complex condition known as tricuspid valve regurgitation may cause concern for patients as it typically doesn’t show signs or symptoms until the disease is severe. So what technologies and therapies do we have to look forward to? Join Dr. Javed Butler as he speaks with Dr. Pedro Villablanca, Structural Heart Interventional Cardiologi...

Guest: Patricia A. Pellikka, M.D. Artificial intelligence (AI) has several applications in cardiology, such as echocardiography. Can machine learning and AI algorithms in echocardiology help clinicians better detect heart failure with preserved ejection fraction (HFpEF)? Dr. Patricia A. Pellikka, Director of the Ultrasound Research Center at the Mayo Clinic, shares data from ACC.23 and explores th...

Guest: Paul Sorajja, MD TRILUMINATE was the first trial to take a look at the impact of tricuspid regurgitation (TR) reduction on patients, and its results may lead to significant improvements in care and quality of life. To learn more about this trial, Dr. Paul Sorajja from the Minneapolis Heart Institute Foundation details the key findings from this trial and explores their impact.

Guest: Ana Barac, MD, PhD The American College of Cardiology's 72nd Scientific Session & Expo featured the latest advancements in all fields of cardiovascular medicine, including cardio-oncology. To learn more, Dr. Javed Butler sits down with Dr. Ana Barac from the MedStar Washington Hospital Center to take a look at clinical data from the STOP-CA trial.

Host: Marius M. Hoeper, MD A recent study explored the safety and efficacy of sotatercept on top of background pulmonary arterial hypertension (PAH) therapy. To learn more about this clinical data, Dr. Marius M. Hoeper, a Professor of Medicine and the Deputy Director of the Department of Respiratory Medicine at Hannover Medical School in Hannover, Germany, dives into the results of this trial and...

Host: Javed Butler, MD Guest: Ana Barac, MD, PhD Cardio-oncology is a novel field in cardiovascular medicine that has rapidly grown over the past few years. What kind of role does multidisciplinary care have in it? Dr. Javed Butler is joined by Dr. Ana Barac from the Inova Heart and Vascular Institute to take a look at where cardio-oncology is and where it could be headed.

According to the CDC, patients with familial hypercholesterolemia or patients who show signs of coronary heart disease are at an increased chance of having heart attack, stroke, and aortic stenosis due to high levels of lipoprotein(a). So how can me manage lipoprotein(a) in our patients? To discuss this, Dr. Mary Katherine Cheeley is joined by fellow ReachMD host Dr. Alan Brown, who’s also the Dir...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Kevin C. Maki, PhD, FNLA, CLS At the American College of Cardiology's 72nd Annual Scientific Session & Expo, cardiologists will gather to explore the latest advancements in the field. Joining us to share what you can expect to learn about statin intolerance at their upcoming session are Dr. Mary Katherine Cheeley and Dr. Kevin Maki.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Laney K. Jones, PharmD, MPH Patients with familial hypercholesterolemia (FH) are at an increased risk of developing coronary heart disease at a young age. So what’s on the horizon for using implementation science strategies in treating patients with FH? Learn more about implementation science as Dr. Mary Katherine Cheeley discusses this...

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Lauren Williams, MCN,RD,LD Kids with dyslipidemia don’t have much different nutritional needs than other young kids their age. However, there are a few key things to be aware of. So how can clinicians meet families where they are to improve their diet? Dive into the unique needs of youth with dyslipidemia as Dr. Mary Katherine Cheeley is...

Host: Matthew Sorrentino, MD Guest: Luke Laffin, MD Six commonly used supplements thought to improve patients’ cholesterol may be doing more harm than good. So what do we need to know about these supplements? To walk us through the results of the SPORT trial, Dr. Matthew Sorrentino is joined by Dr. Luke Laffin, Co-Director of the Center for Blood Pressure Disorders at the Cleveland Clinic.

Host: Javed Butler, MD Guest: Scott Solomon, MD Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction (DELIVER trial) is a study designed to assess the effectiveness of SGLT2 inhibitors in patients with higher left ventricular ejection fraction. To help lead the discussion on the results of this study, Dr. Javed Butler is joined by Dr. Scott Solomon, lead study author a...